Frédéric Debelle
Research Subjects
Frédéric Debelle has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Fabrice Gankam
Department of Nephrology and Dialysis CH EpiCURA Baudour Belgium
2 shared publicationsA Albert
Informatique médicale et Biostatistique, Université de Liège, Liège, Belgium
1 shared publicationAhmed Goubella
Department of Nephrology, Hospital Centre EpiCURA, Baudour, Belgium
1 shared publicationAnne‐Emilie Declèves
Department of Metabolic and Molecular Biochemistry, Research Institute for Health Sciences and Technology University of Mons Mons Belgium
1 shared publication- Annick Massart
Department of Nephrology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium
1 shared publication B Maes
H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium
1 shared publication
Latest Publications
- Open Access
- 18 September 2023
- Published by Wiley in Seminars in Dialysis
- Vol. 37 (2) , 145-152
Monitoring strategy of COVID‐19 vaccination in dialysis patients based on a multiplex immunodot method: The CovidDial study
Introduction: COVID-19 vaccine was demonstrated to be effective in dialysis patients, but boosters are mandatory due to a rapid waning of anti-spike antibodies. A vaccination strategy based on immunologic response might be useful to maintain a favorable risk-benefit balance in this vulnerable population. Methods: CoviDial is an observational prospective study enrolling 121 dialysis patients to receive a 3-dose mRNA-1273 vaccine according to a uniform schedule. At baseline, months 1, 3, 6, 9, and 12, anti-spike antibodies against four epitopes (S1, S2, ECD-S1 + S2, RBD) were monitored with a multiplex immunodot enzymatic assay. Potential correlation between initial serologic response and subsequent COVID-19 infection was then assessed. Results: Overall, 96.2% and 96.8% of patients had anti-RBD antibodies at 3 and 12 months, respectively. All antibodies titers significantly decreased at month 6 compared to month 3. Booster vaccine induced a robust serologic response at month 9, but with a waning 3 months later, particularly for anti-S2 (37.2 +/- 3.3 vs. 61.3 +/- 3.0, p < 0.0001) and anti-S1 + S2 antibodies (68.4 +/- 3.3 vs. 88.4 +/- 2.3, p = 0.0015). Fifteen patients were later tested positive for SARS-CoV-2. At month 3, mean titers of anti-RBD, anti-S1 + S2, and anti-S2 antibodies were lower in the subsequent SARS-CoV-2 infected cohort (71.57 +/- 9.01 vs. 85.79 +/- 2.61, p = 0.0131; 41.07 +/- 7.96 vs. 61.68 +/- 3.56, p = 0.0237; 13.79 +/- 5.03 vs. 39.70 +/- 3.86, p = 0.0096; respectively). Conclusion: Three doses of mRNA-1273 vaccine induce a robust but time-limited immunologic response in dialysis patients. Lower anti-spike antibodies titers after initial vaccination are associated with a higher risk to subsequently contract SARS-CoV-2, even beyond 6 months.
- 18 September 2023
- Published by Wiley in Seminars in Dialysis
- Vol. 37 (2) , 145-152
Open AccessMonitoring strategy of COVID‐19 vaccination in dialysis patients based on a multiplex immunodot method: The CovidDial study
Introduction: COVID-19 vaccine was demonstrated to be effective in dialysis patients, but boosters are mandatory due to a rapid waning of anti-spike antibodies. A vaccination strategy based on immunologic response might be useful to maintain a favorable risk-benefit balance in this vulnerable population. Methods: CoviDial is an observational prospective study enrolling 121 dialysis patients to receive a 3-dose mRNA-1273 vaccine according to a uniform schedule. At baseline, months 1, 3, 6, 9, and 12, anti-spike antibodies against four epitopes (S1, S2, ECD-S1 + S2, RBD) were monitored with a multiplex immunodot enzymatic assay. Potential correlation between initial serologic response and subsequent COVID-19 infection was then assessed. Results: Overall, 96.2% and 96.8% of patients had anti-RBD antibodies at 3 and 12 months, respectively. All antibodies titers significantly decreased at month 6 compared to month 3. Booster vaccine induced a robust serologic response at month 9, but with a waning 3 months later, particularly for anti-S2 (37.2 +/- 3.3 vs. 61.3 +/- 3.0, p < 0.0001) and anti-S1 + S2 antibodies (68.4 +/- 3.3 vs. 88.4 +/- 2.3, p = 0.0015). Fifteen patients were later tested positive for SARS-CoV-2. At month 3, mean titers of anti-RBD, anti-S1 + S2, and anti-S2 antibodies were lower in the subsequent SARS-CoV-2 infected cohort (71.57 +/- 9.01 vs. 85.79 +/- 2.61, p = 0.0131; 41.07 +/- 7.96 vs. 61.68 +/- 3.56, p = 0.0237; 13.79 +/- 5.03 vs. 39.70 +/- 3.86, p = 0.0096; respectively). Conclusion: Three doses of mRNA-1273 vaccine induce a robust but time-limited immunologic response in dialysis patients. Lower anti-spike antibodies titers after initial vaccination are associated with a higher risk to subsequently contract SARS-CoV-2, even beyond 6 months.
- Open Access
- 1 June 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (6) , 1732-1737
Kidney Thrombotic Microangiopathy After COVID-19 Associated With C3 Gene Mutation
- 1 June 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (6) , 1732-1737
Open AccessKidney Thrombotic Microangiopathy After COVID-19 Associated With C3 Gene Mutation
- 1 July 2013
- Published by Peeters Publishers in Acta Clinica Belgica
- Vol. 68 (4) , 275-281
CINACALCET FOR MANAGING SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS IN CLINICAL PRACTICE IN BELGIUM: A 16-MONTH OBSERVATIONAL STUDY (ECHO-B)
In Belgium, the calcimimetic cinacalcet is initially reimbursed for ≤ 4 months in dialysis patients with secondary hyperparathyroidism (SHPT) and intact parathyroid hormone (iPTH) ≥ 800 pg/mL, or iPTH 300-800 pg/mL and Ca × P > 55 mg2/dL2 despite ≥ 6 months’ optimal treatment with vitamin D sterols and/or phosphate binders. The Belgian, multicentre, observational study ECHO-B evaluated cinacalcet in such patients. Patients who began cinacalcet treatment after March 1, 2007 were eligible. Data were collected retro/prospectively from 6 months before until 16 months after starting cinacalcet (whether or not cinacalcet was continued). Median iPTH was markedly elevated (816 [IQR 551-991] pg/mL) at baseline (the time of starting cinacalcet), but decreased continuously over the course of the study, reaching a value of 414 pg/mL (IQR 240-641; median change -41%) at 4 months, 335 pg/mL (IQR 159-616; -60%) at 12 months and 250 pg/mL (IQR 172-436; -64%) at 16 months. Reductions in serum calcium (-7%) and phosphorus (-13%) were already (near) maximal at 4 months. The primary outcome (iPTH 150-300 pg/mL and/or a ≥ 30% reduction within 4 months of tarting cinacalcet; criterion for continued reimbursement in Belgium) was achieved in 65/81 patients (80%; 95% CI 72-89%). Results show that in dialysis patients with SHPT in real-life clinical practice, mineral metabolism improves after starting cinacalcet: our study findings suggest that PTH levels may continue decreasing after 12 months’ treatment in this setting.
- 1 July 2013
- Published by Peeters Publishers in Acta Clinica Belgica
- Vol. 68 (4) , 275-281
CINACALCET FOR MANAGING SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS IN CLINICAL PRACTICE IN BELGIUM: A 16-MONTH OBSERVATIONAL STUDY (ECHO-B)
In Belgium, the calcimimetic cinacalcet is initially reimbursed for ≤ 4 months in dialysis patients with secondary hyperparathyroidism (SHPT) and intact parathyroid hormone (iPTH) ≥ 800 pg/mL, or iPTH 300-800 pg/mL and Ca × P > 55 mg2/dL2 despite ≥ 6 months’ optimal treatment with vitamin D sterols and/or phosphate binders. The Belgian, multicentre, observational study ECHO-B evaluated cinacalcet in such patients. Patients who began cinacalcet treatment after March 1, 2007 were eligible. Data were collected retro/prospectively from 6 months before until 16 months after starting cinacalcet (whether or not cinacalcet was continued). Median iPTH was markedly elevated (816 [IQR 551-991] pg/mL) at baseline (the time of starting cinacalcet), but decreased continuously over the course of the study, reaching a value of 414 pg/mL (IQR 240-641; median change -41%) at 4 months, 335 pg/mL (IQR 159-616; -60%) at 12 months and 250 pg/mL (IQR 172-436; -64%) at 16 months. Reductions in serum calcium (-7%) and phosphorus (-13%) were already (near) maximal at 4 months. The primary outcome (iPTH 150-300 pg/mL and/or a ≥ 30% reduction within 4 months of tarting cinacalcet; criterion for continued reimbursement in Belgium) was achieved in 65/81 patients (80%; 95% CI 72-89%). Results show that in dialysis patients with SHPT in real-life clinical practice, mineral metabolism improves after starting cinacalcet: our study findings suggest that PTH levels may continue decreasing after 12 months’ treatment in this setting.